SYRE · Spyre Therapeutics, Inc.
$97.12
-2.85 (-2.85%)
At close · Jul 29
Going-concern doubt
— flagged May 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed May 5, 2026
Market Cap
$8.68B
Shares
86.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$155.2M
+25.4%
FY2025
Operating Margin
-27347.97%
-23707.7pp
FY2023
Diluted EPS
$13.76
+155.3%
FY2023
Operating Cash Flow
-$169.25M
-7.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $886K | $2.33M | $18.74M | $0 | $0 | $3.89M | $5.21M | $4.63M | — | — | |
| $190.44M | $171.65M | $162.79M | $89.5M | $58.58M | $57.07M | $59.64M | $64.6M | $36.72M | $22.82M | $18.14M | $11.45M | $6.83M | |
| $51.2M | $47.91M | $45.78M | $39.95M | $28.53M | $27.32M | $21.84M | $15.73M | $12.63M | $10.07M | $8.39M | $5.95M | $2.07M | |
| — | $0 | $0 | $744K | $1.57M | $1.58M | $996K | $418K | $293K | $249K | $132K | $89K | $19K | |
| $201.64M | $209.56M | $208.57M | $243.19M | $87.11M | $84.39M | $81.48M | $80.33M | $49.35M | $32.88M | $26.53M | $17.4M | $8.9M | |
| -$201.64M | -$209.56M | -$208.57M | -$242.3M | -$84.78M | -$65.65M | -$81.48M | -$80.33M | -$45.46M | -$27.68M | -$21.91M | -$11.32M | -$8.9M | |
| — | — | — | -27347.97% | -3640.23% | -350.33% | — | — | -1169.32% | -531.72% | -473.34% | — | — | |
| — | -$209.56M | -$208.57M | -$241.56M | -$83.21M | -$64.07M | -$80.49M | -$79.92M | -$45.17M | -$27.43M | -$21.77M | -$11.23M | -$8.89M | |
| $22.2M | $54.34M | $599K | -$96.51M | $830K | -$11K | $588K | $2.08M | $1.12M | $440K | $208K | $20K | -$1.44M | |
| — | — | — | — | -$83.95M | -$65.66M | -$80.89M | -$78.25M | — | — | — | — | — | |
| -$179.44M | -$155.22M | -$207.97M | -$338.82M | -$83.95M | -$65.66M | -$80.89M | -$78.25M | — | — | — | — | — | |
| $0 | -$15K | $51K | -$26K | -$136K | $141K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$179.44M | -$155.2M | -$208.02M | -$338.79M | -$83.82M | -$65.8M | -$80.89M | -$78.25M | -$44.35M | -$27.24M | -$21.7M | -$11.3M | -$10.35M | |
| — | — | — | -38238.15% | -3598.75% | -351.14% | — | — | -1140.64% | -523.27% | -468.84% | — | — | |
| — | — | — | — | — | — | — | — | — | -$27.24M | -$21.7M | -$11.52M | -$10.35M | |
| -$180.88M | -$154.51M | -$208.14M | -$338.44M | -$83.84M | -$65.83M | -$80.93M | -$78.18M | -$44.27M | -$27.33M | -$21.7M | -$11.3M | -$10.35M | |
| USD/shares | — | — | — | $13.76 | -$24.86 | -$25.02 | -$38.00 | — | — | — | — | — | — |
| USD/shares | — | — | — | $13.76 | -$24.86 | -$25.02 | -$38.00 | — | — | — | — | — | — |
| shares | — | — | — | 6.9M | 3.37M | 2.63M | 2.13M | 1.28M | 832.9K | 605.13K | 391.67K | 23.99K | — |
| shares | — | — | — | 6.9M | 3.37M | 2.63M | 2.13M | 1.28M | 832.9K | 605.13K | 391.67K | 23.99K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.73×
EV/EBIT
—
Peer median 24.96×
P/E (TTM)
—
Peer median 19.19×
Peer medians compare against the 155 similar-size Biotechnology companies (of 522 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $0 | $0 | $886,000 | $2,329,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Development Fee and Royalty | $0 | $0 | $886,000 | $2,329,000 | $6,739,000 | — | — |
| Development Fee | — | — | — | — | — | $0 | $0 |
| License | — | — | — | — | $12,000,000 | $0 | $0 |
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
22 filings
22 filers
Visit website
Investor relations